Abstract
Highly active antiretroviral therapy (HAART) and direct acting antiviral agents (DAAs) are key elements in the effective pharmacotherapy of human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) respectively. These two chronic illnesses affect millions of persons at any given time, though only a select proportion has been eligible for successful treatment. With the development of newer, safer and more effective antiviral therapies it is expected that a greater proportion of those infected will have access to these life-saving therapies. However, it is also important to appreciate that this very population will also be subject to increased toxicities from these agents. In this review we outline the published nephrotoxic effects of select new agents used in the management of HIV and HCV, specifically commenting, where possible, on the role of epithelial organic transporters in explaining the said renal toxicities.
Keywords: Antiviral therapy, HCV, HIV, renal.
Current Drug Metabolism
Title:The Role of Organic Transporters in Pharmacokinetics and Nephrotoxicity of Newer Antiviral Therapies for HIV and Hepatitis C
Volume: 16 Issue: 4
Author(s): Donald Mitema and Mohamed G. Atta
Affiliation:
Keywords: Antiviral therapy, HCV, HIV, renal.
Abstract: Highly active antiretroviral therapy (HAART) and direct acting antiviral agents (DAAs) are key elements in the effective pharmacotherapy of human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) respectively. These two chronic illnesses affect millions of persons at any given time, though only a select proportion has been eligible for successful treatment. With the development of newer, safer and more effective antiviral therapies it is expected that a greater proportion of those infected will have access to these life-saving therapies. However, it is also important to appreciate that this very population will also be subject to increased toxicities from these agents. In this review we outline the published nephrotoxic effects of select new agents used in the management of HIV and HCV, specifically commenting, where possible, on the role of epithelial organic transporters in explaining the said renal toxicities.
Export Options
About this article
Cite this article as:
Mitema Donald and Atta G. Mohamed, The Role of Organic Transporters in Pharmacokinetics and Nephrotoxicity of Newer Antiviral Therapies for HIV and Hepatitis C, Current Drug Metabolism 2015; 16 (4) . https://dx.doi.org/10.2174/138920021604150902181109
DOI https://dx.doi.org/10.2174/138920021604150902181109 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Progress of Nano-drug Delivery System for Liver Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Magnetic Nanoparticles: New Players in Antimicrobial Peptide Therapeutics.
Current Protein & Peptide Science Dimethylaminoparthenolide, A Water Soluble Parthenolide, Suppresses Lung Tumorigenesis Through Down-Regulating the STAT3 Signaling Pathway
Current Cancer Drug Targets IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Therapeutic Transfer of DNA Encoding Adenoviral E1A
Recent Patents on Anti-Cancer Drug Discovery Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Review of Progress in Predicting Protein Methylation Sites
Current Organic Chemistry Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma
Current Drug Targets Upfront DPD Deficiency Detection to Secure 5-FU Administration: Part 2- Application to Head-and-Neck Cancer Patients
Clinical Cancer Drugs Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Approaches to Gastrointestinal Cytoprotection: From Isolated Cells, Via Animal Experiments to Healthy Human Subjects and Patients with Different Gastrointestinal Disorders
Current Pharmaceutical Design Targeting Microenvironment of Melanoma and Head and Neck Cancers in Photodynamic Therapy
Current Medicinal Chemistry Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Current Cancer Drug Targets Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism MicroRNA-21 as a Novel Therapeutic Target
Current Cancer Therapy Reviews